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The pathophysiologic process of Alzheimer’s disease (AD) begins years before the diagnosis of 
clinical dementia. This concept of preclinical AD has arisen from the observation of AD patho-
logic findings such as senile plaques and neurofibrillary tangles in the brains of people who at 
the time of death had normal cognitive function. Recent advances in biomarker studies now 
provide the ability to detect the pathologic changes of AD, which are antecedent to symptoms 
of the illness, in cognitively normal individuals. Functional and structural brain alterations that 
begin with amyloid-β accumulation already show the patterns of abnormality seen in individu-
als with dementia due to AD. The presence of preclinical AD provides a critical opportunity for 
potential interventions with disease-modifying therapy. This review focuses on the studies of 
antecedent biomarkers for preclinical AD.
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Preclinical Alzheimer’s Disease
A definite diagnosis of Alzheimer’s disease (AD) requires his-
topathological evidence via autopsy or brain biopsy. Senile 
plaques (SPs) and neurofibrillary tangles (NFTs) are the main 
neuropathological hallmarks of AD,
1 and these are used as cri-
teria for making the pathological diagnosis of AD.
2-4 Howev-
er, lesions such as SPs and NFTs can be also observed in cog-
nitively normal elderly people.
5 SPs are extracellular deposits 
of amyloid in the gray matter of the brain, and NFTs are ab-
normal tau aggregations within the neurons of the brain. Am-
yloid deposition has been estimated to begin perhaps 10 years 
or more prior to any clinical signs of dementia. This deposi-
tion progresses with time until it reaches a plateau.
5 In addi-
tion, abnormal tau aggregation, which appears to begin inde-
pendently during normal aging and in the early stages of AD, 
is further accelerated by the concomitant amyloid pathology.
5,6 
That is, by the time the clinical dementia just starts to be de-
tectable, densities of SPs and NFTs sufficient to meet the path-
ological criteria for a diagnosis of AD have already been es-
tablished.
7 These findings have led to the concept of preclinical 
AD. The time gap between the neuropathological changes and 
the clinical cognitive changes of AD is called preclinical AD.
5,8 
The onset of very mild dementia is related to synaptic and neu-
ronal loss that is presumed to eventually result from the path-
ological progresses underlying the formation of SPs and NFTs 
(Table 1).
9 There is little or no neuronal loss in aging or preclini-
cal AD, but there is substantial loss in very mild AD. Recent 
autopsy data have confirmed that gross cerebral atrophy, indi-
cating the loss of synapses and neurons, is the pathological sub-
strate of the cognitive impairment in AD patients.
10
The clinical course of AD commences with a presymptom-
atic or preclinical phase. With preclinical AD, it is assumed 
that the AD pathologic process in cognitively normal elderly 
people results in progressive neurodegeneration, and that af-
fected individuals will develop symptomatic AD if they live 
long enough, although the time to symptomatic AD may be in-
fluenced by brain and cognitive reserve,
11,12 and by other fac-
tors that are currently unknown. Next is symptomatic AD, 
which is further divided into two phases according to the clini-Shim YS and Morris JC
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cal severity. The second phase is thus a prodromal phase of 
AD, and is commonly known as mild cognitive impairment 
(MCI),
13 and the third phase in the evolution of AD is demen-
tia, which is defined as impairments in multiple domains that 
are severe enough to produce loss of function.
Biomarkers of AD
Research on the biomarkers of AD has made great progress, 
and especially with regard to the use of biomarkers as diagnos-
tic and prognostic tools. To date, cerebrospinal fluid (CSF) as-
says of amyloid β (Aβ) and tau, and amyloid imaging with 
Pittsburgh compound B (PIB)-positron-emission tomography 
(PET) are considered to be molecular biomarkers for AD. Flu-
orodeoxyglucose (FDG)-PET studies of brain metabolism and 
MRI of brain structure are downstream markers of the presence 
of AD pathology. These findings are also used to support the 
revised National Institute of Neurological and Communicative 
Disorders and Stroke and the Alzheimer’s Disease and Relat-
ed Disorders Association criteria for the research diagnosis of 
AD.
14 Moreover, there is sufficient evidence that these bio-
markers can be used to predict who will progress from MCI to 
AD or from normal to MCI or AD.
15,16
Powerful, unbiased screening approaches utilizing highly 
sensitive proteomics techniques and novel applications of mass 
spectrometry are now producing a revolution in biomarker 
discovery. The use of genetics in combination with biomarkers 
will likely provide more diagnostic and prognostic information 
than the use of biomarkers alone. However, this review focus-
es on the most widely studied and well validated fluid and im-
aging biomarkers, as mentioned briefly above. The positive 
links between these biomarkers and AD pathology are summa-
rized (Table 2), and studies searching for the antecedent bio-
markers in preclinical AD are introduced.
Table 1. Relationships between aging, preclinical Alzheimer’s disease (AD), and AD
Aging Preclinical AD Very mild AD
Plaques in neocortex None or a few Many neuritic & diffuse plaques Many neuritic & diffuse plaques
Tangles in entorhinal cortex &  
  hippocampus/CA1
Few to many  
  (increases with age)
Many Many
Cell loss in entorhinal cortex &  
  hippocampus/CA1
None Little to none Substantial (30-60%)
Clinical diagnosis Normal, CDR 0 Normal, CDR 0 Very mild dementia or MCI, CDR 0.5
Pathological diagnosis Normal AD AD
CA: cornu ammonis, CDR: clinical dementia rating, MCI: mild cognitive impairment (Modified from Ref. 9, with permission).
Table 2. Selective fluid and imaging biomarkers of AD
Biomarker Observations in AD Related pathophysiology
Fluid biomarkers
CSF Aβ42 1. Decreased Amyloid load
2. Predictive of conversion from MCI to AD (nonfibrillar, diffuse plaques)
Plasma Aβ 1. Increased Aβ42 & decreased Aβ40 in FAD
CSF tau/p-tau 1. Increased  Tau hyperphosphorylation
2. Predictive of conversion from MCI to AD (p-tau231)
CSF ratios of tau species to Aβ42 1. Increased
2. Predictive of conversion from normal to MCI or AD
CSF isoprostanes 1. Increased in AD CSF Oxidative stress
2. Predictive of conversion from normal to MCI or AD
3. Increased in preclinical FAD mutation carriers
Plasma e1-antichymotrypsin 1. Predictive of AD risk Neuroinflammation
Imaging biomarkers
PIB-PET 1. Increased retention Amyloid load (fibrillar)
FDG-PET 1. Regional hypometabolism Synaptic dysfunction
2. Predictive of conversion from MCI to AD
MRI 1. Regional & whole brain atrophy Neuronal loss
2. Predictive of conversion from MCI to AD, from normal to MCI
AD: Alzheimer's disease, CSF: cerebrospinal fluid, Aβ: amyloid beta, FAD: familial AD, p-tau: phosphorylated tau, PIB: pittsburg com-
pound B, PET: positron-emission tomography, FDG: fluorodeoxyglucose, MRI: magnetic resonance imaging (Modified and updated 
from Ref. 15, with permission from Elsevier).Biomarkers of Preclinical AD
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Fluid biomarkers
CSF	Aβ
Aβ peptides are generated from the cleavage of amyloid pre-
cursor protein (APP) by β- and γ-secretases.
17 Aβ40 and Aβ42 are 
the most common isoforms among those that are 39-43 amino 
acid residues long.
17 Levels of total CSF Aβ and Aβ40 do not 
differentiate individuals with AD from controls,
18,19 although it 
has been shown that CSF Aβ40 levels are decreased in individ-
uals with cerebral amyloid angiopathy.
20 However, levels of 
CSF Aβ42 are commonly decreased in patients with AD,
21 pos-
sibly because Aβ42 is the main component of AD plaques,
22 
which may function as sinks or traps for Aβ42,
23 thus decreas-
ing the amount of Aβ42 cleared from the brain to the CSF. 
However, decreased CSF Aβ42 levels have also been reported 
in non-AD dementias such as frontotemporal dementia (FTD), 
vascular dementia, Creutzfeldt-Jakob disease, and dementia 
with Lewy bodies.
24-26 A possible limitation of AD studies that 
have used CSF Aβ as a marker is the lack of standardization 
for Aβ quantification. Furthermore, little is known about the in-
fluences of normal aging on CSF Aβ turnover and clearance. 
An important consideration is the normal circadian variability 
of the CSF Aβ40 and Aβ42 levels,
27 indicating that differences 
in the time of day at which CSF is collected may contribute to 
variability of results. Levels of CSF Aβ42 do not correlate well 
with the disease duration or severity,
28 a finding that is consis-
tent with results from PIB-PET studies showing that amyloid 
retention does not change appreciably in symptomatic AD.
29 
These findings suggest that amyloid pathology occurs very 
early in the disease process and may have stabilized by the 
time the clinical signs of dementia appear.
Several studies have investigated CSF Aβ42 levels in con-
junction with those of tau. Sunderland et al.
28 assayed 131 AD 
patients and 72 controls and performed a meta-analysis of 17 
studies on CSF Aβ42 levels and 34 studies on CSF tau levels. 
In their own cohort, they observed significantly lower mean 
CSF Aβ42 level and higher CSF tau levels in the AD patients 
compared to controls. The results of the meta-analysis were 
similar, with a difference in the two levels between the AD pa-
tients and the controls.
While plasma Aβ42 levels are increased and those of Aβ40 de-
creased in individuals with autosomal dominant, familial AD,
30 
most groups have reported no difference in the plasma Aβ lev-
els between individuals with sporadic AD and controls.
31-33 
The diagnostic utility of plasma Aβ has been further limited by 
its short half life in the plasma (typically 5-15 min), its pres-
ence in very low concentrations, and by the additional periph-
eral sources of Aβ production and clearance, which can be in-
fluenced by confounding factors (such as renal function).
CSF	tau
Many studies found that the CSF tau levels were increased in 
AD patients.
19,21,25,28,34,35 Increased levels of CSF tau are mark-
ers of neuronal injury from multiple causes and can be seen in 
other neurodegenerative disorders such as FTD, stroke, and 
Creutzfeldt-Jakob disease.
35 Increased CSF tau is not specific 
for AD, but does correlate with clinical disease severity, with 
higher concentrations associated with greater cognitive im-
pairment in individuals with normal cognition and in patients 
with AD.
36
In AD, tau undergoes abnormal hyperphosphorylation. As a 
result, it is unlikely to be able to bind and stabilize microtu-
bules, possibly leading to axon degeneration, and so the in-
crease in CSF tau in AD patients would be due to the release 
of tau from degenerating neurons and its subsequent diffusion 
into the CSF.
37 Studies have shown consistently that phos-
phorylated tau (p-tau) offers equivalent and possibly better di-
agnostic utility for AD than total tau. In contrast to the total tau, 
p-tau is not increased secondary to acute brain injury, which 
further increases its diagnostic specificity.
Enzyme-linked immunosorbent assays have been developed 
to recognize various phosphorylated epitopes.
38 The results of 
studies comparing the diagnostic accuracy of different phos-
phorylation sites such as p-tau231, p-tau181, and p-tau199 sug-
gest that all three are equally effective in differentiating AD 
patients from controls.
39 While p-tau231 appears to provide 
diagnostic specificity for AD and to improve the differentia-
tion between AD and FTD,
40 there is evidence that p-tau181 
improves the differentiation between AD and dementia with 
Lewy bodies.
39
Imaging biomarkers
Structural	MRI
Neuropathological studies have documented an abundance of 
NFTs and significant neuronal loss in the hippocampus and 
entorhinal cortex of AD patients.
1,8 Atrophy of the medial tem-
poral areas, including the hippocampus and entorhinal cortex, 
has been observed on brain MRI of AD patients.
41,42 Structur-
al MRI thus offers an indirect marker of neuronal atrophy and 
loss of brain tissue, which are hallmarks of the neurodegener-
ative pathology of AD. Meta-analyses have confirmed the abil-
ity of MRI to distinguish AD subjects from controls, with vol-
umetric studies of the medial temporal lobe and hippocampus 
having a sensitivity of 78-94% and specificity of 60-100%.
43
In addition to discriminating AD from controls, volume 
measurements of the entorhinal cortex and hippocampus have 
been shown to discriminate MCI patients who later progress 
to AD dementia from those who do not.
44,45 Longitudinal stud-
ies have demonstrated that the rate of whole-brain atrophy in-Shim YS and Morris JC
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creases more in early-AD patients than in controls.
46,47 In addi-
tion, a recent study found that the rate of ventricular volume 
expansion predicted future MCI in nondemented cohorts that 
were followed for up to 15 years, and that this rate further ac-
celerated years prior to the diagnosis of MCI, suggesting that 
this measurement is also useful as an antecedent biomarker.
48
As a surrogate of neurodegeneration, NFT formation, and 
neuronal and synaptic loss,
49,50 MRI may correlate better with 
cognitive function than CSF biomarkers in cross-sectional and 
longitudinal studies.
51,52 Structural markers that reflect rates of 
atrophy can also be useful for monitoring disease progression 
and severity. Volumetric measures of the hippocampus are al-
ready being employed as secondary endpoints in several phar-
macologic trials, and in the near future, these measurements may 
be approved as surrogate endpoints and secondary outcome 
variables in trials of potential disease-modifying therapies.
Metabolic	FDG-PET
PET has been employed in many AD studies to examine the 
regional cerebral metabolic rate for glucose (rCMRGLc) using 
18F-2-deoxy-2-fluoro-D-glucose as a marker. A reduction of 
glucose metabolism, as seen on PET in the bilateral temporal 
parietal regions and in the posterior cingulate, is the most com-
monly described diagnostic criterion for AD.
53 A meta-analysis 
of nine studies revealed that the pooled sensitivity and speci-
ficity were both 86% for temporoparietal hypometabolism 
when discriminating AD patients from healthy controls.
54
In addition, a decreased rCMRGLc in the hippocampus was 
found to be indicative of who will progress to MCI among a 
group of cognitively normal individuals.
55 Similarly, in longi-
tudinal studies of individuals with MCI, the individuals who 
progressed to AD dementia had significant rCMRGLc reduc-
tions in the hippocampus and temporal neocortex as compared 
to those who did not progress.
56 Consistent with the knowledge 
that the entorhinal cortex is one of the earliest affected areas in 
AD, hypometabolism therein has also been shown to accu-
rately predict a decline to MCI or a Clinical Dementia Rating 
(CDR)57 score of 0.5 (CRD 0.5) with a sensitivity of 83% and a 
specificity of 85%.
58 Jagust et al. reported that FDG-PET corre-
lated well with CSF Aβ42 levels and with cognitive function.
59
Molecular	PIB-PET
PET imaging using 
11C-labeled PIB {2-[4’-(methylamino) 
phenyl]-6-hydrobenzothiazole} ligand has been one of the ma-
jor diagnostic tools in AD.
60 PIB binds with high affinity and 
high specificity to fibrillar Aβ in neuritic plaques and cerebral 
amyloid angiopathy.
29 In AD patients, PIB retention is in-
creased in the frontal, parietal, temporal, and occipital cortices, 
and in the striatum, and studies have consistently shown that 
nearly all patients diagnosed with dementia of the Alzheimer 
type (DAT) are PIB positive [PIB(+)].
29,61
Interestingly, a longitudinal study of AD patients who were 
taking cholinesterase inhibitors and/or the NMDA (N-methyl-
D-aspartic acid) antagonist found that PIB retention did not 
change over a 2-year period of follow-up, although the cortical 
rCMRGLc decreased.
62 This suggests that amyloid deposition 
reaches a maximum early in the course of AD, and indeed sev-
eral studies have found that MCI subjects have PIB uptake in 
the same range as that of AD patients.
29,63 In one study, initial 
PIB retention was predictive of disease progression over the 
next 2 years.
29
Recent results from clinical trials of the 
18F-labeled tracer 
18F-AV-45 are promising for the next generation of amyloid 
imaging. It has several unique characteristics that make it suit-
able for Aβ plaque imaging in the human brain: excellent bind-
ing affinity, highly selective for Aβ plaque labeling, excellent 
brain penetration, and rapid kinetics in animal studies.
64 Stud-
ies suggest that 
18F-AV-45 is a sensitive marker for the presence 
of amyloid in cortical gray matter in elderly individuals, and 
can differentiate between groups of subjects with AD, MCI, 
and normal cognitive function.
65 At the International Confer-
ence on Alzheimer’s Disease in 2010, Clark et al. reported their 
phase 3 histopathology data (http://www.alzforum.org/new/de-
tail.asp?id=2507). Similarly to the previous analysis of six au-
topsy cases,
66 Clark and his colleagues found a near-perfect 
correlation between PET imaging using the new tracer and am-
yloid load measured postmortem in the same patients. In that 
study they tested florbetapir (formerly 
18F AV-45) in 35 people 
who were expected to die within 6 months. Of the 19 subjects 
who met National Institute on Aging-Reagan criteria for AD pa-
thology, all but 1 were amyloid-positive on PET, as judged by 
visual interpretation (97% accuracy), and all 19 came out posi-
tive on standard uptake value ratio quantification of PET data 
(100% accuracy). For both PET analysis methods, all 16 who 
lacked postmortem AD pathology were also amyloid-negative 
by live brain imaging, giving the tracer a specificity of 100% in 
this study.
Search for antecedent biomarkers  
of preclinical AD
Biomarkers	to	detect	preclinical	AD
Since amyloid deposition is known to precede clinical signs of 
dementia, PIB-PET may facilitate the early detection of amy-
loid during preclinical AD. In fact, up to 30% of cognitively 
normal elderly people demonstrate substantial PIB retention in 
the cortex by their mid-70s, and this PIB retention is similar in 
extent to that of patients with mild-to-moderate AD.
67 These 
findings were expanded further by Fagan et al.,
34,68 who report-
ed an inverse relationship between CSF Aβ42 levels and brain Biomarkers of Preclinical AD
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amyloid load, as measured by PIB-PET. These findings sug-
gest that a low CSF Aβ42 level is an excellent marker of amy-
loid deposition, independent of clinical status. PIB binding and 
CSF Aβ42 levels did not consistently correspond with clinical 
diagnosis. Cognitively normal (CDR 0) individuals who are 
PIB(+) with a low CSF Aβ42 level have cerebral deposits of 
amyloid in the absence of cognitive impairment (i.e., preclini-
cal AD). These observations suggest strongly that the CSF Aβ42 
level is a highly sensitive and specific marker for the presence 
or absence of amyloid in the brain (regardless of the clinical di-
agnosis), and so it may serve, either alone or in combination 
with PIB-PET, as an antecedent biomarker of AD.
68 This im-
portant finding suggests that the inadequate sensitivity and 
specificity of CSF Aβ42 for distinguishing between clinical 
groups reflects contamination of the control group with preclini-
cal cases of AD, and perhaps misdiagnoses of non-AD demen-
tias in the DAT group.
In addition to decreased Aβ42 levels, CSF levels of tau (and 
the specific p-tau species) are increased in individuals with 
AD. There are significant overlaps in the tau levels as well as 
the Aβ42 levels between AD patients and controls. Aggregation 
of Aβ plays a necessary part in AD, and especially in the pre-
clinical phase of the disease. Aggregation of the microtubule-
associated protein tau begins in cognitively normal individuals 
and appears to correlate with neurodegeneration. CSF tau ele-
vation can be observed in cognitively normal individuals and 
may mark the transition from cognitive normality to symptom-
atic AD. In preclinical AD, CSF tau levels are correlated with 
the amount of amyloid deposition.
6
Preclinical	AD	is	not	benign
It has been shown that elevated amyloid burden, as measured 
by PIB-PET or CSF Aβ42 levels, is associated with longitudi-
nal cognitive decline and regional brain atrophy. In a longitu-
dinal study of cognitively normal adults, Morris et al.
69 ob-
served that cognitively normal individuals who later progress 
to CDR 0.5 DATqqq initially had a higher PIB uptake. This 
finding suggests that cortical amyloid is predictive of future 
cognitive decline and symptomatic AD. In addition, reduced 
CSF Aβ42 levels were associated with brain atrophy in cogni-
tively normal individuals, but not in patients with AD.
70,71 Pre-
clinical AD is not benign, and Aβ aggregation seems to drive 
neurodegeneration in the preclinical phase.
6
The ratios of CSF tau/Aβ42 and p-tau/Aβ42 in cognitively 
normal individuals strongly and significantly predict progres-
sion to a CDR >0 or MCI. Li et al. reported that over a follow-
up period of 42 months, all of those subjects who converted to 
MCI had elevated CSF tau/Aβ42 ratios, while none of them 
converted among those with a normal ratio.
72 It appears that 
cognitively normal elderly people with high ratios have already 
developed Aβ deposition and neurodegeneration, and so this 
most likely represents preclinical AD. In a study by Fagan et al., 
70% of those subjects with high ratios (as compared to only 
10% of those subjects with a normal ratio) converted from 
CDR 0 to CDR >0 after 3-4 years.
34 In that study, the CSF tau/
Aβ42 and p-tau/Aβ42 groups did less well, and the levels of plas-
ma Aβ42 did not correlate with PIB status. This observation 
suggests that the CSF Aβ42 level decreases with amyloid depo-
sition, and that amyloid plaques act as a sink.
The	time	course	of	biomarker	abnormalities	during	
preclinical	AD
Brain amyloid can be assessed based on represented as reduc-
tions in the CSF Aβ42 levels and increased PIB retention. Ele-
vated CSF tau is thought to be a biomarker of tau-mediated 
neuronal injury and neurodegeneration. Decreased FDG uptake 
on PET in the temporoparietal area is a biomarker of AD-re-
lated synaptic dysfunction, and brain atrophy seen on structur-
al MRI and involving the medial temporal lobe is a biomarker 
of AD-related neurodegeneration. The fluid and imaging bio-
markers parallel the pathophysiological sequence of AD and 
are linked with AD pathology. Abnormal accumulation of Aβ42 
in oligomeric forms is an early event in the pathophysiologic 
cascade of AD that ultimately manifests as cerebral deposits of 
Aβ. Through mechanisms that remain to be elucidated, it is pos-
tulated that the accumulation of Aβ leads to synaptic dysfunc-
tion, neurodegeneration, and eventually neuronal loss. Although 
it is further accelerated by the concomitant amyloid pathology, 
abnormal tau aggregation also begins independently during nor-
mal aging.
5,6
Preclinical AD is characterized by significant Aβ deposition 
and lesser degrees of tau aggregation, with minimal neuronal 
loss. The biomarkers related to amyloid plaques become ab-
normal first, and a substantial amyloid load accumulates prior 
to the appearance of clinical dementia. Decreases in CSF Aβ42 
levels may precede amyloid retention, as detected by PIB-PET, 
signifying what is perhaps the first evidence of AD pathology 
in cognitively normal individuals.
68,70 A case report of the clin-
ical, cognitive, and CSF markers of AD in an individual who 
progressed from cognitive normality to early symptomatic AD 
suggests that changes in these biomarkers precede the detection 
of cerebral fibrillar amyloid using PIB-PET.
73 Nonfibrillar ce-
rebral Aβ deposits or diffuse SPs are already pathognomonic, 
and they are not benign.
While amyloid and tau pathologies in preclinical AD are in-
evitably associated with some degree of neuronal, axonal, and 
synaptic loss, and neuronal injury, it is only after a threshold 
of neuronal loss has been reached in specific neocortical re-
gions that clinical signs of dementia appear. These markers ap-
pear to correlate better with clinical impairment than the amy-Shim YS and Morris JC
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loid load. Structural MRI is the last biomarker to become 
abnormal. However, MRI retains a closer relationship with 
cognitive performance later into the disease than other bio-
markers (Fig. 1).
The	adult	children	study	and	the	dominantly	inherited	
alzheimer	network
Perhaps the most important role of biomarkers, and the most 
needed at present, is the identification of individuals who are 
cognitively normal but who have evidence of AD pathology 
(i.e., preclinical AD). Such individuals can be identified with 
antecedent biomarkers such as the CSF Aβ42 and tau, and with 
PIB, and they are the most likely to benefit from future disease-
modifying therapies.
There have been many trials to establish validated anteced-
ent biomarkers. The Adult Children Study, which is a longitu-
dinal assessment of middle-aged to elderly cognitively normal 
individuals, is currently evaluating potential indicators of in-
cipient disease through an analysis of cognition, personality, 
genetics, biomarkers, and neuroimaging in a group of normal 
healthy people aged between 45 and 74 years. The individuals 
have been stratified into those with a parent who had AD and 
those for whom neither parent had AD. All of the subjects are 
subjected to MRI, FDG-PET, and PIB-PET amyloid imaging, 
and psychometric testing with a follow-up every 2 years; CSF 
biomarker analyses are also being performed. In 241 cogni-
tively normal participants, the PIB-assessed amyloid burden 
increased as a function of the 2 known risk factors for AD: age 
and apolipoprotein ε4 (ApoE4).
74 In the study participants, 
PIB uptake increased according to age, and a group of cogni-
tively normal ApoE4-positive older individuals (mean age in 
the late 50s) showed a mean decrease in CSF Aβ42, but no 
change in CSF tau relative to an age-matched group of ApoE4-
negative individuals. Cerebral Aβ42 deposition is the pathobio-
logical phenotype of ApoE4, and this increases as a function of 
age in preclinical AD patients.
The Dominantly Inherited Alzheimer Network will estab-
lish an international registry of mutation carriers and noncarri-
ers from families with presenilin (PSEN) 1, PSEN 2, or APP 
mutations. The purpose of the Dominantly Inherited Alzheim-
er Network is to compare mutation carriers and noncarriers to 
determine the chronology and order of imaging and biomark-
er changes that predict symptomatic AD, to compare the clin-
ical and pathological phenotypes of dominantly inherited AD 
with those of late-onset AD, and to maintain a publicly avail-
able resource of data and biospecimens. Presymptomatic car-
riers of AD mutations such as PSEN 1 and APP exhibit de-
creased CSF Aβ42 and increased CSF tau.
75,76
These studies have compared candidate biomarkers be-
tween high- and low-risk groups, from which promising bio-
markers may be obtained through immediate comparison of 
samples therefrom. The high-risk groups used for these kinds 
of studies could be defined by genetic variables, for example, 
presymptomatic individuals with familial AD mutations
77 or 
carriers of ApoE4.
78 Other risk factors could also be used to de-
fine risk groups, such as those with advanced age
79 or a family 
history of AD.
80
Conclusions
Aβ and tau as the main pathological substrates of AD have 
driven the search for the biomarkers of AD. Of course, the 
pathophysiology of AD involves many more processes than Aβ 
deposition and NFT formation. APP is cleaved by β-secretase 
and γ-secretase complexes. Once released in monomer form, 
Aβ may form oligomers that are neurotoxic. Aβ accumulates 
and aggregates to form plaques. Once Aβ has formed oligo-
mers and amyloid deposits, microglial cells become activated 
and migrate toward the plaques. Astrocytes become reactive, 
and numerous inflammatory mediators, oxidative processes, 
and protein-folding activities are released. Dendrites and axo-
ns around the plaques become dystrophic due to a transporta-
tion defect. The brain metabolism changes as Aβ is deposited 
in the small or large vessel walls. Neuronal injury and synaptic 
Fig. 1. Hypothetical cascade of pathophysiology and related bio-
markers in Alzheimer’s disease (AD). APP: amyloid precursor pro-
tein, CSF: cerebrospinal fluid, Aβ: amyloid beta, SP: senile plaque, 
NFT: neurofibrillary tangle, PIB: pittsburg compound B, p-tau: phos-
phorylated tau, FDG: fluorodeoxyglucose, PET: positron-emission 
tomography, MRI: magnetic resonance imaging.
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loss develop in addition to formation of NFTs, and then neu-
rons die (Fig. 1). Each of these changes may also cause altera-
tions in the composition of the CSF and plasma, and these 
changes may be therapeutic targets for disease-modifying ther-
apies. Biomarkers can lead to the early diagnosis of AD and can 
be used to detect preclinical AD. Convincing evidence has ex-
panded the scope of AD research, and so new biomarkers have 
been included in the diagnostic criteria of the proposed revi-
sions of National Institute of Neurological and Communicative 
Disorders and Stroke and the Alzheimer’s Disease and Relat-
ed Disorders Association (www.alz.org/research/diagnostic_
criteria/). The operational research criteria suggest that we can 
diagnose preclinical AD with just the findings of Aβ accumu-
lation according to PIB retention or a low CSF Aβ42 level, in 
addition to synaptic dysfunction and early degeneration such 
as hypometabolism seen on FDG-PET, cortical thinning or hip-
pocampal atrophy on MRI, and elevated CSF levels of tau or 
p-tau. Moreover, these findings are used as surrogate outcome 
measures to predict the time course of future cognitive decline. 
However, we should distinguish between clinical criteria and 
the research criteria.
While there have been promising results related to determin-
ing the antecedent biomarkers of AD, the reliability and valid-
ity of biomarkers and definition of the cut-off values need to 
be established. Moreover, we should not neglect the neuropsy-
chological assessments for making the diagnosis of early AD, 
although clinical evaluations, by definition, will not identify the 
presence of preclinical disease. It is important to remember the 
potential that behavioral markers hold for AD. A study observ-
ing the transition from healthy aging to symptomatic AD found 
a sharp inflection point followed by an accelerating decline in 
multiple domains of cognition (not just in memory) during the 
preclinical period of AD when there was insufficient cognitive 
decline to warrant a clinical diagnosis with the aid of conven-
tional criteria.
81 Additional longitudinal studies of older indi-
viduals could provide more information, and perhaps by com-
bining biomarkers with other measures that can sensitively 
detect very subtle cognitive decline.
The long preclinical phase has profound implications for AD 
therapeutic strategies. Since potential intervention with disease-
modifying therapies may provide the greatest chance of pre-
serving normal cognition, it will be critical to identify individ-
uals with preclinical AD before the development of cognitive 
deficits and concomitant neuronal loss. Thus, there may be a 
paradigm shift in AD from cure to prevention. The hope is that 
in the future, AD will be managed in the way cardiovascular 
disease is handled now. Physicians will use lifestyle factors and 
diagnostic measures to define the risk of AD in their patients, 
followed by manipulation of their diet, lifestyle, and medica-
tions to delay or prevent the symptomatic onset of this disease.
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